Protective effect of Tanreqing injection on axon myelin damage in the brain of mouse model for experimental autoimmune encephalomyelitis  by Fan, Yongping et al.
TOPIC
JTCM |www. journaltcm. com October 15, 2014 |Volume 34 | Issue 5 |
Online Submissions: http://www.journaltcm.com J Tradit Chin Med 2014 October 15; 34(5): 576-583
info@journaltcm.com ISSN 0255-2922
© 2014 JTCM. All rights reserved.
EXPERIMENTAL STUDY
Protective effect of Tanreqing injection on axon myelin damage in
the brain of mouse model for experimental autoimmune encephalo-
myelitis
Yongping Fan, Tao Yang, Qi Zheng, LeiWang, Chunxiao Yuan, Ling Fang, Kangning Li
aa
Yongping Fan, Tao Yang, Chunxiao Yuan, Kangning Li,
Department of Traditional Chinese Medicine, Beijing Tiantan
Hospital, Capital Medical University, Beijing 100050, China
Qi Zheng, Lei Wang, Ling Fang, School of Traditional Chi-
nese Medicine, Capital Medical University, Beijing 100069,
China
Supported by the Research on the Effect of Catalpol on the
OPCs' Proliferation and Differentiation (No. 81173237) and
Research on the Impact of OPCs and Remyelination via the
Method of Bushenyisu with EAE mice (No. 81072765) of Na-
tional Natural Science Foundation
Correspondence to: Prof. Yongping Fan, Department of
Traditional Chinese Medicine, Beijing Tiantan Hospital, Capi-
tal Medical University, Beijing 100050, China. yong-
pingf@hotmail.com
Telephone: +86-10-67096665
Accepted: January 19, 2014
Abstract
OBJECTIVE: To evaluate the effect of Tanreqing in-
jection on axon myelin in the mouse brain of exper-
imental autoimmune encephalomyelitis (EAE).
METHODS: An EAE model was established by my-
elin oligodendrocyte glycoprotein (MOG)35-55 immu-
nization in C57BL/6 mice. Mice were randomly di-
vided into the following groups: normal, model,
prednisone acetate (PA) (6 mg/kg), Tanreqing high
dose (5.14 mL/kg), Tanreqing low dose (2.57 mL/
kg). On the day of immunization, both Tanreqing
groups were treated by intraperitoneal injection,
with the PA group treated by intragastrical perfu-
sion after T cell response, and the other groups
treated with saline. Changes in body weight, neuro-
logical deficit score, incidence rate, mortality rate,
and course of disease were observed for all mice.
Brain tissue was isolated and stained with hematox-
ylin-eosin, and pathological investigations per-
formed to evaluate axon myelin damage by trans-
mission electron microscopy (TEM). Myelin basic
protein and microtubule associated protein-2 were
analyzed by immunohistochemistry.
RESULTS: Tanreqing injection significantly pro-
longed EAE latency and decreased the neurological
deficit score, alleviated infiltration of inflammatory
cells in the focus area, up-regulated hippocampal
MBP expression at the acute stage and the remis-
sion stage, and increased microtubule associated
protein-2 expression in the EAE brain to varying de-
grees in the acute stage. TEM analysis indicated
that Tanreqing injection alleviates myelin damage
in the EAE mouse and maintains the integrity of cir-
cular layer structures and alleviates axon mitochon-
drial swelling.
CONCLUSION: Tanreqing injection alleviates EAE
symptoms.
© 2014 JTCM. All rights reserved.
Key words: Multiple sclerosis; Encephalomyelitis,
autoimmune, experimental; Tanreqing injection;
Myelin basic protein; Microtubule-associated pro-
teins
INTRODUCTION
Multiple sclerosis (MS) is a chronic inflammatory de-
myelinating disease of the central nervous system
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(CNS) and is mediated by T cell immunity,1-4 leading
to CNS demyelination, and damage to oligodendro-
cyte axons.5 It is the most commonly seen CNS disease
for young people.6 Glucocorticoids and interferon are
commonly used to treat MS, but there is no effective
way to prevent its recurrence.7-10 Oligodendrocytes are
the main CNS gliocyte and function by encircling the
axon to form myelin. When MS occurs, oligodendro-
cytes are attacked by T-cells, inducing myelin damage.
Damage to myelin is a key pathogenic mechanism of
MS, and how to prevent and treat such damage has be-
come the key to treating MS/experimental autoim-
mune encephalomyelitis (EAE). Use of multiple my-
elin oligodendrocyte glycopeptides (MOG) 35-55 to in-
duce EAE in C57BL/6 mice is an important compo-
nent of modern MS research. Tanreqing is composed
of Huangqin (Radix Scutellariae Baicalensis), Ling-
yangjiao (Cornu Saigae Tataricae), Jinyinhua (Flos
Lonicerae), and Lianqiao (Fructus Forsythiae Suspensae).
Clinically, it is used to effectively treat acute cerebral
ischemia, infantile acute pneumonia, and acute chole-
cystitis.11,12 Animal experiments relieve inflammatory re-
sponse of pyohemia and resist endotoxin action by de-
creasing high mobility group box 1 protein (HMGB1)
in the rat.13,14
In the present study, changes in the extent of infiltrat-
ing inflammatory cells, myelin basic protein (MBP) ex-
pression, and microtubule associated protein-2
(MAP-2) in the brain of EAE mice were observed with
HE staining and immuno-histochemical methods. My-
elin damage was assessed by transmission electron mi-
croscopy (TEM) to probe the effects of Tanreqing in-
jection on myelin during EAE pathological progression.
MATERIALS ANDMETHODS
Animals
Female specific pathgen free (SPF) grade C57BL/6
mice (n=100, 7-8 weeks of age, weighing 18-22 g),
were supplied by Beijing Wei Tong Li Hua Experimen-
tal Animals Technique Co., Ltd., (Beijing, China), and
raised at the Center of Experimental Animals, Capital
Medical University (Beijing, China). All experimental
procedures were approved by the Institutional Animal
Care Committee of Capital Medical University.
Drugs and reagents
Tanreqing injection was supplied by Shanghai Kaibao
Pharmacy Co., Ltd., (Shanghai, China). Prednisone ac-
etate (PA) was supplied by Pacific Pharmacy Co., Ltd.,
(Tianjin, China). MOG35-55 (MEVGWYRSPFSRVVH-
LYRNGK) was synthesized by Kangwei Shiji Bio-Sci-
ence and Technology Co., Ltd., (Beijing, China). Com-
plete Freund's adjuvant (CFA) and pertussis toxin
(PTX) were supplied by Sigma (St. Louis, MO, USA).
Tubercusis (H37Ra, TB) was produced by Difco Com-
pany (St. Agnes, Corpus Christi, TX, USA). Rabbit an-
ti-MBP and anti-MAP-2 were purchased from Abcam
(St. Barry, MA, USA). Rabbit ultra-sensitive two-step
kits (PV-9001), concentrating type DAB kits
(ZLI-9017/9018/9019) were purchased from Beijing
Zhongshan Jinqiao Company (Beijing, China). Xylol,
absolute ethanol, paraformaldehyde, chloral hydrate,
glutaraldehyde, sodium chloride, sodium dihydrogen
phosphate, disodium hydrogen phosphate, and other
routine reagents were supplied by Beijing Chemical Re-
agent Company (Beijing, China).
Preparation of the EAE model
Mice were randomly divided into 4 groups by random
number table method: normal, model, PA, Tanreqing
high dose, and Tanreqing low dose groups, with 20
mice in each group. 10 mg MOG35-55 and 120 mg TB
were dissolved with 20 mL saline, mixed with 20 mL
CFA, and repeatedly whipped until formation of an an-
tigen emulsion of oil-wrapping-water shape. The
mixed antigen emulsion was injected into four subcuta-
neous points on both sides of the back middle line on
EAE mice. On the day of immunization (day 0) and at
48 h, PTX 500 ng (0.2 mL)/mouse was intra-abdomi-
nally injected to induce EAE. Mice in the normal
group were injected with saline.
Treatment methods
On the day of immunization, the mice in the Tanreq-
ing high dose and low dose groups were treated by in-
tra-abdominal injection (5.14 and 2.57 mL/kg, respec-
tively) for 40 days. The PA group was treated by intra-
gastric perfusion of PA (6 mg/kg) on the 9th day after
T cell response, and other groups were treated by saline
(10 mL/kg) for 40 days. The response and changes in
body weight and behavior were observed. Additionally,
response latency, incidence rate, and mortality were cal-
culated.
Observation of indices
The response latency, incidence rate, and mortality of
EAE mice were calculated. Nervous system symptoms
were assessed by commonly-used 0-5 grade criteria:15,16
grade 0: normal; grade 1: dystonia of tail; grade 2: par-
tial paralysis of hind limbs or unstable gait; grade 3:
complete paralysis of hind limbs; grade 4: partial or
complete paralysis of fore limbs; and grade 5: mori-
bund condition or death. On the 21st day (peak symp-
toms) and 40th day (remission recovery) following im-
munization, mice were sacrificed, with 10 mice at each
time point in each group. From each group, two mice
were taken for fixation with glutaraldehyde and ob-
served with TEM after staining. The other mice were
fixed with paraformaldehyde, dehydrated, imbedded
with paraffin, sectioned, and pathological changes ob-
served after HE staining. Changes in MBP and MAP-2
expression were detected by immunohistochemical
methods, and integrated optic density (IOD) was deter-
mined with NIS-Elements BR 3.2 software (Nikon,
Melville, NY, USA), and statistical analysis performed.
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Preparation for histopathologic investigation
Anesthesia (10% chloral hydrate, 0.35 mL/kg) was in-
jected intraperitoneally prior to histology. Blood was
evacuated with saline from the right auricle for 5 min
and perfusion conducted with paraformaldehyde for
10 min. The brain and spinal cord were separated
and placed into paraformaldehyde for epoxy and pres-
ervation.
Detection of laboratory indices
For HE staining, the following steps were conducted:
incubation in xylol for 2 × 15 min and 100% alcohol
for 2×5 min, followed by 80% alcohol 5 min, and dis-
tilled water for 5 min, before staining with hematoxy-
lin solution for 5 min. Samples were then rinsed with
hematoxylin solution and running water for 2 s, 1%
hydrochloric acid in alcohol for 2 s, distilled water for
20 s, distilled water for 2 s, and then stained with
0.5% eosin for 3 min. Samples were then washed with
distilled water for 2 s, 80% alcohol for 2 s, 95% alco-
hol for 2 s, absolute ethanol 5 min, carbol-xylol for
5 min, xylol for 3×2 min, and then mounted with neu-
tral resin.
IHC staining
Paraffin sections were put into citrate buffer for anti-
gen repair after deparaffinization, rinsed with PBS,
cooled at room temperature for 30-40 min, incubated
in 3% H2O2 for 10 min, treated with the first antigen,
then incubated at 4℃ overnight, then placed at room
temperature for 1 h. The second antigen was added
and incubated at 37℃ , and developed with DAB for
1 min. After dehydration and mounting with neutral
resin, slides were observed by optical microscopy. IOD
was determined with NIS-Elements BR 3.2 software
(Nikon,Tokyo, Japan) and statistical analysis performed.
Preparation for electron microscopy
White matter and gray matter tissue were cut into
small pieces of 1 mm2, and fixed with 3% glutaralde-
hyde for 2 h, washed three times for 10 min with 0.1
phosphate buffer solution (PBS), fixed with 1% osmic
acid, and washed three times for 10 min with 0.1 PBS.
Slides were then dehydrated with alcohol for 10 min at
each step: 100% alcohol 2×15 min; 100% acetone 2×
15 min, and immersed into embedding medium of
low viscosity (1∶1) for 4 h. Embedding medium was
exposed to air overnight and placed into pure embed-
ding medium for 4 h, and polymerized at 37℃ for
24 h. Samples were then stained with uranium acetate
for 30 min, rinsed three times with water, stained with
lead nitrate for 20 min, and rinsed once with NaOH
followed by two water rinses.
Statistical process
The data are expressed as mean ± standard deviation
( xˉ ± s). SPSS 16.0 (Version 16.0, International Busi-
ness Machines Corporation, Chicago, IL, USA) statisti-
cal software was used for data analysis. Normality tests
was carried out and ANOVA used for those exhibiting
normality, otherwise the rank test was used. P<0.05
was regarded as statistically significant.
RESULTS
Changes in incidence rate, mortality rate, and
latency
The incidence rate in the EAE model group was
100%, with the mortality rates in both the model and
Tanreqing high dose groups at 7%. Notably, the Tan-
reqing high dose group latency was prolonged com-
pared with the Tanreqing low dose group (P<0.05)
(Table 1).
Changes of nervous function scores
The EAE mice experienced a T cell response on the
8th day following immunization. The mice in the mod-
el group were listless, experienced a reduction in body
weight or slowed growth, ruffled hair, and exhibited hy-
poactivity. After displaying symptoms of an impaired
nervous system, the mice showed tail weakness, a stag-
gering gait, hind limb paralysis, locomotion difficulty,
paralysis of all four limbs, and even death. EAE mice
reached peak symptoms on day 15, and on day 21 the
nervous system function score in all treatment groups
decreased to some extent. Notably, on days 32 and 40,
all the treatment groups were different compared with
the model group (P<0.01) (Table 2).
Histopathological changes
HE staining indicated that in the normal brain, struc-
tures were in good order, complete, and the cytoplasm
and cell nuclei of nerve cells were clear, with scattered
neuroglia cells, very few lymphocytes around small
veins. In all EAE model groups, infiltration of inflam-
Group
Model
PA
Tanreqing high dose
Tanreqing low dose
Dose
-
6 mg/kg
5.14 mL/kg
2.57 mL/kg
Incidence rate (%)
100
100
100
100
Mortality rate (%)
7
0
7
0
Latency (days)
11.2±1.9
10.9±2.2
11.9±1.9
11.2±1.9a
Notes: model group was treated by saline (10 mL/kg) for 40 days, PA group was treated by intragastric perfusion of PA (6 mg/kg) on the
9th day after T cell response, Tanreqing high dose and low dose groups were treated by intra-abdominal injection for 40 days (5.14 and
2.57 mL/kg, respectively). PA: prednisone acetate. Compared with the Tanreqing high dose group, aP<0.05.
Table 1 The EAE incidence rate, mortality rate, and latency of EAE mice ( xˉ ±s)
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matory cells and solidification of nervous cell nuclei
around the small blood vessels in the brain could be
seen at the acute stage, and both gray and white matter
were involved. Inflammation was located mainly
around the third cerebral and lateral ventricles. At the
acute stage, lymphocytes aggregated around blood ves-
sels and formed a typical sleeve-shape. Lymphocyte in-
filtration could still be seen during remission, but this
was alleviated to some extent compared with that at
the acute stage. Pathological changes of the brain in all
the treatment groups were relieved to varying degrees
(Figure 1).
Changes in the brain observed with TEM
TEM analysis of acute stage EAE indicated that the cir-
cular layer structure of myelin was intact in controls,
with neurofilaments and neuromicrotubules exhibiting
a natural density and order. Synaptic structure and mi-
tochondrial shape were also normal. However, EAE
mice exhibited a circular layer structure and deformed,
loose myelin, with separation of lamellar layers show-
ing hair-like changes. Additionally, axons appeared in-
jured, marked by local enlargement and mitochondria
lysosomes were swollen and deformed, although ill-de-
fined crista were not obvious, or even lacking altogeth-
er. In all treatment groups, the loose deformation of
the circular layer structures was alleviated to varying de-
grees, with milder injury of the axon compared with
the model group (Figure 2).
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Group
Model
PA
Tanreqing high dose
Tanreqing low dose
n
5
5
5
5
Day 0
0.00±0.00
0.00±0.00
0.00±0.00
0.00±0.00
Day 10
0.50±0.49
0.57±0.73
0.27±0.50
0.83±1.03a
Day 15
2.13±0.79
2.03±0.88a
2.25±0.70
2.77±0.56bc
Day 21
2.35±0.78
1.10±0.22b
1.64±0.48b
1.88±0.69d
Day 32
2.30±0.54
0.80±0.22b
1.43±0.61bd
1.50±0.71bd
Day 40
2.20±0.54
0.60±0.22b
1.43±0.84bd
1.43±0.77bd
Notes: model group was treated by saline (10 mL/kg) for 40 days, PA group was treated by intragastric perfusion of PA (6 mg/kg) on the
9th day after T cell response, Tanreqing high dose and low dose groups were treated by intra-abdominal injection for 40 days (5.14 and
2.57 mL/kg, respectively). PA: prednisone acetate. Compared with the model group, aP<0.05, bP<0.01; compared with the PA group, cP<
0.01, dP<0.05.
Table 2 Changes of nervous system function scores ( xˉ ±s)
Figure 1 Pathological changes in EAE brain
A1, A2: normal group; B1, B2: model group; C1, C2: PA group; D1, D2: Tanreqing high dose group; E1, E2: Tanreqing low dose
group at the acute stage and remission stage, respectively. Model and normal group were treated by saline (10 mL/kg) for 40
days, PA group was treated by intragastric perfusion of PA (6 mg/kg) on the 9th day after T cell response; Tanreqing high dose and
low dose groups were treated by intra-abdominal injection for 40 days (5.14 and 2.57 mL/kg, respectively). EAE: experimental au-
toimmune encephalomyelitis; PA: prednisone acetate.
A1 B1 C1 D1 E1
A2 B2 C2 D2 E2
A B C D E
Figure 2 TEM images of changes in EAE brain
A: normal group; B: model group: C: PA group; D: Tanreqing high dose group; E: Tanreqing low dose group at the acute stage.
Model and normal groups were treated by saline (10 mL/kg) for 40 days, PA group was treated by intragastric perfusion of PA (6
mg/kg) on the 9th day after T cell response; Tanreqing high dose and low dose groups were treated by intra-abdominal injection
for 40 days (5.14 and 2.57 mL/kg, respectively). TEM: transmission electron microscopy; EAE: experimental autoimmune encepha-
lomyelitis; PA: prednisone acetate.
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Immunohistochemical analysis of MBP
There were significant differences in MBP expression
in the cortex by day 21 (Table 3). The normal group
exhibited elevated expression compared with all other
groups (P<0.01). MBP expression in the model hippo-
campus DG differed compared with the Tanreqing
high dose and low dose groups (P<0.01), whereas PA
mice showed decreased expression. Hippocampal DG
MBP expression in the Tanreqing high dose group was
the highest, compared with the other experimental
groups (P<0.01, P<0.05).
MBP expression in hippocampal DG and CA1 areas in
the Tanreqing high dose low dose groups were elevated
compared with the model group (P<0.01, P<0.05, re-
spectively) (Table 4). There were no significant differ-
ences between groups in MBP expression in the hippo-
campal CA1 area and the lateral ventricle (Table 4, Fig-
ure 3).
Immunohistochemical analysis of MAP-2
On day 21, MAP-2 expression differed between nor-
mal and all model groups in the cortex, hippocampal
DG and CA1, and lateral ventricle (P<0.01, P<0.05).
There were also expression differences between the
model group cortex relative to the Tanreqing high and
low dose groups (P<0.01, P<0.05). Hippocampal CA1
Group
Normal
Model
PA
Tanreqing high dose
Tanreqing low dose
n
5
5
5
5
5
Cortex
200±29
157±17a
156±35a
153±11a
159±17a
Hippocampus DG area
67±14
39±13a
48±14ad
76±7be
53±18cb
Hippocampus CA1 area
157±54
102±19c
123±35d
107±12a
101±19a
Lateral ventricle
143±22
122±27c
154±40d
115±31af
135±34b
Table 3 Integrated optic density of brain MBP at day 21 ( xˉ ±s)
Notes: model and normal groups were treated by saline (10 mL/kg) for 40 days; PA group was treated by intragastric perfusion of PA (6 mg/
kg) on the 9th day after T cell response; Tanreqing high dose and low dose groups were treated by intra-abdominal injection for 40 days
(5.14 and 2.57 mL/kg, respectively). MBP: myelin basic protein; PA: prednisone acetate. Compared with the normal group, aP<0.01, cP<
0.05; compared with the model group, bP<0.01, dP<0.05; compared with the PA group, eP<0.01, fP<0.05.
Notes: model and normal groups were treated by saline (10 mL/kg) for 40 days; PA group was treated by intragastric perfusion of PA (6 mg/
kg) on the 9th day after T cell response; Tanreqing high dose and low dose groups were treated by intra-abdominal injection for 40 days
(5.14 and 2.57 mL/kg, respectively). MBP: myelin basic protein; PA: prednisone acetate. Compared with the normal group, aP<0.01, cP<
0.05; compared with the model group, bP<0.01, dP<0.05.
Group
Normal
Model
PA
Tanreqing high dose
Tanreqing low dose
n
5
5
5
5
5
Cortex
200±35
129±20a
187±36b
126±14a
126±22a
Hippocampus DG area
67±14
35±13a
42±14a
54±10b
49±12cd
Hippocampus CA1 area
116±62
86±24
95±33
93±19
76±12
Lateral ventricle
154±17
125±8
135±46
119±12
132±15
Table 4 Integrated optic density of brain MBP at day 40 ( xˉ ±s)
Figure 3 MBP changes in EAE brain
A1, A2: normal; B1, B2: model; C1, C2: PA; D1, D2: Tanreqing high dose; E1, E2: Tanreqing low dose at the acute stage and on day
40, respectively. Model and normal groups were treated by saline (10 mL/kg) for 40 days; PA group was treated by intragastric per-
fusion of PA (6 mg/kg) on the 9th day after T cell response; Tanreqing high dose and low dose groups were treated by intra-ab-
dominal injection for 40 days (5.14 and 2.57 mL/kg, respectively). MBP: myelin basic protein; EAE: experimental autoimmune en-
cephalomyelitis; PA: prednisone acetate.
A1 B1 C1 D1 E1
A2 B2 C2 D2 E2
580
JTCM |www. journaltcm. com October 15, 2014 |Volume 34 | Issue 5 |
Fan YP et al. / Experimental Study
A1 B1 C1 D1 E1
A2 B2 C2 D2 E2
Figure 4 MAP-2 changes in the EAE brain
A1, A2: normal, B1, B2: model, C1, C2: PA, D1, D2: Tanreqing high dose, E1, E2: Tanreqing low dose at the acute stage and remis-
sion stage, respectively. Model and normal groups were treated by saline (10 mL/kg) for 40 days; PA group was treated by intra-
gastric perfusion of PA (6 mg/kg) on the 9th day after T cell response; Tanreqing high dose and low dose groups were treated by
intra-abdominal injection for 40 days (5.14 and 2.57 mL/kg, respectively). MAP-2: microtubule associated protein-2; EAE: experi-
mental autoimmune encephalomyelitis; PA: prednisone acetate.
Group
Normal
Model
PA
Tanreqing high dose
Tanreqing low dose
n
5
5
5
5
5
Cortex
120±20
63±13a
78±15a
91±27ac
93±23bd
Hippocampus DG area
48±10
22±5a
27±8a
22±9a
21±6a
Hippocampus CA1 area
72±22
40±13a
48±13a
59±19bd
49±17bd
Lateral ventricle
126±28
68±20a
72±23a
62±9a
68±8a
Table 5 Integrated optic density of MAP-2 in the brain of EAE mice on day 21 ( xˉ ±s)
Notes: model and normal groups were treated by saline (10 mL/kg) for 40 days; PA group was treated by intragastric perfusion of PA (6 mg/
kg) on the 9th day after T cell response; Tanreqing high dose and low dose groups were treated by intra-abdominal injection for 40 days
(5.14 and 2.57 mL/kg, respectively). EAE: experimental autoimmune encephalomyelitis; MAP-2: microtubule associated protein-2; PA:
prednisone acetate. Compared with the normal group, aP<0.01, bP<0.05; compared with the model group, cP<0.01, dP<0.05.
Group
Normal
Model
PA
Tanreqing high dose
Tanreqing low dose
n
5
5
5
5
5
Cortex
140±17
68±7a
102±15ab
75±24ac
69±6ac
Hippocampus DG area
53±10
28±7a
40±10de
43±16de
50±11e
Hippocampus CA1 area
98±21
63±11a
80±15d
61±13a
60±15a
Lateral ventricle
110±16
77±9a
99±10
77±21a
85±19a
Table 6 Integrated optic density of MAP-2 in the brain of EAE mice on day 40 ( xˉ ±s)
Notes: model and normal groups were treated by saline (10 mL/kg) for 40 days; PA group was treated by intragastric perfusion of PA (6 mg/
kg) on the 9th day after T cell response; Tanreqing high dose and low dose groups were treated by intra-abdominal injection for 40 days
(5.14 and 2.57 mL/kg, respectively). EAE: experimental autoimmune encephalomyelitis; MAP-2: microtubule associated protein-2; PA:
prednisone acetate. Compared with the normal group, aP<0.01, dP<0.05; compared with the model group, bP<0.01, eP<0.05; compared
with the PA group, cP<0.01.
MAP-2 expression of Tanreqing high and low dose
groups is higher than the model and PA groups (P<
0.01, P<0.05) (Table 5, Figure 4).
We also observed MAP-2 expression differences in
the cerebral cortex, hippocampus CA1 and DG, and
lateral ventricle during remission on day 40 relative
to controls (P<0.01, P<0.05). Interestingly, there
were also differences between the PA and model
groups in the cortex, hippocampal DG (P<0.01, P<
0.05), and between the Tanreqing high dose group
and the PA cortex, hippocampal CA1 and DG, and
lateral ventricle (P<0.01) (Table 6, Figure 4).
DISCUSSION
Tanreqing injection is composed of Huangqin (Radix
Scutellariae Baicalensis), Lingyangjiao (Cornu Saigae Ta-
taricae), Jinyinhua (Flos Lonicerae), and Lianqiao (Fruc-
tus Forsythiae Suspensae). Huangqin (Radix Scutellariae
Baicalensis) is a monarch drug that clears heat, drys
dampness, purges fire, and removes toxic substances. It
clears heat of the upper-jiao, but it is mostly used to
treat hepatitis, jaundice, renal infection, myocardial
ischemia and other diseases.17-19 Lingyangjiao (Cornu
Saigae Tataricae) reduce heat and remove toxic sub-
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stances, resolving phlegm and relieving spasms, and
Jinyinhua (Flos Lonicerae), and Lianqiao (Fructus For-
sythiae Suspensae) function reduce fever and remove tox-
ins, dispelling stagnated heat. They together function
to reduce fever and remove toxicity, suggesting they
might be suitable for the initial stage of MS/EAE. Clin-
ically, Tanreqing injection improves action on hypoxae-
mia and other pathological states of acute lung injury,
inflammatory exudation of the alveolus and microvas-
cular injury induced by infection,13,20 and inhibits viral
proliferation in cells and strengthens immune system
function.21 TCM holds that "the kidney is in charge of
bones and produces marrow which above joins in the
brain as marrow sea" and that it joins the spinal col-
umn and spinal cord. After many years of clinical and
experimental studies, understanding the basic patho-
genesis of MS continues to progress. These include kid-
ney deficiency and stagnation of phlegm, tonifying kid-
ney, resolving phlegm, and promotion of blood circula-
tion, which might be used as a basic treatment method
for MS. However, during the early stages of MS,
phlegm coagulation and accumulation of toxic sub-
stances are the main pathogenesis. Tanreqing injection
reduces fever, resolves phlegm, and removes toxins, act-
ing mainly on phlegm coagulation in the body to treat
acute MS/EAE.
In the present experiment, MOG35-55 was used to im-
munize C57BL/6 mice to establish an EAE model with
pathologic symptoms.22,23 Our results indicate that Tan-
reqing injection alleviates impairment of nervous func-
tion at the acute stage and the remission stage (on days
21, 32, and 40), and that PA treatment demonstrated
potential therapeutic action. HE staining at the peak
stage indicated an elevated number of inflammatory
cells around the veins in the brain, which is a primary
factor that induces EAE. The extent of infiltrating in-
flammatory cells at the acute stage and the remission
stage was superior in the Tanreqing low dose group
compared with the model group.
Many studies indicate that demyelination and axon
damage are the main pathological changes of MS/EAE.
MBP is a protein expressed by a specific kind of oligo-
dendrocyte, Schwann cells, before formation of the my-
elin sheath. Myelin sheaths commonly form a membra-
nous lamellar structure with phospholipids, ensuring
nervous system impulse conduction, which is an impor-
tant index for assessing demyelination.24,25 Importantly,
myelin sheath formation is attacked by T cells in the in-
flammatory response.26-29 Oral administration of MBP
for treatment of EAE has been reported abroad.30,31 In
those experiments, expression of hippocampal MBP
following Tanreqing treatment was up-regulated at the
acute and remission stage. TEM of Tanreqing low dose
mice revealed that myelin damage was alleviated, and
circular layer structures were kept intact. In the model
group, the circular layer structure was loose and de-
formed, with prominent hair-like changes. This sug-
gests that Tanreqing provides protection for myelin in
EAE mice.
MAP-2 is an important cytoskeleton protein, closely
correlated with nervous system plasticity, and is an im-
portant marker for repairing damaged axons and den-
drites.32,33 Such damage occurs mainly in the soma, den-
drite, dendritic spine, and the dense postsynaptic area
of neurons in the central nervous system, which plays
an important role in branching and extending den-
drites. MAP-2, as a member of the microtubule-associ-
ated protein family, an important component for stabi-
lizing cellular microtubules, plays an important role in
neurogenesis, and is an essential prerequisite for the
proliferation and differentiation of oligodendrocyte pre-
cursors and forming functional axons.34,35 The hippo-
campus is a center of learning and memory and is easi-
ly injured by inflammatory responses of the central ner-
vous system.36 We observed MAP-2 expression in the
brain of both Tanreqing treatment groups increased to
varying degrees at the acute EAE stage, protecting axo-
ns from damage in the cortex and hippocampal CA1
area. TEM results showed that axon mitochondria
swelled, with disturbances to energy metabolism in the
model group. These changes were alleviated to varying
degrees in both treatment groups, indicating that Tan-
reqing injection offers protection to axons.
In summary, Tanreqing injection alleviates injury of
the myelin sheath in the hippocampus and cerebral cor-
tex in EAE mice, providing a partial experimental ratio-
nale for treatment of MS.
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